KeifeRx’s TKI technologies are designed to leverage mechanisms of action inherent to TKIs which thus far have been underexplored. This includes the ability to penetrate the brain, induce autophagy, and enable the bulk disposal of disease-causing toxic proteins to treat neurodegenerative diseases, and the ability to target mast cells and simultaneously modulate peripheral and central immunity, providing therapeutic potential for an array of immune diseases.
Compelling preclinical and clinical research conducted at Georgetown University by KeifeRx’s co-founder, Charbel Moussa, MBBS, Ph.D., has demonstrated the ability of TKIs to enable protein clearance and eliminate the inflammatory response. These properties offer the potential to significantly improve upon current neurodegenerative and immune disease treatments, which are primarily palliative and offer minimal and temporary benefits due to their inability to adequately eliminate toxic proteins and mitigate inflammation.
CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
Long-Term Safety and Clinical Effects of Nilotinib in Parkinson’s Disease
Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer’s Disease